AstraZeneca and Lilly move Alzheimer's drug into big trial
AstraZeneca and Eli Lilly said they had started a large trial of their experimental Alzheimer's drug, seen as a promising, but still risky, approach for slowing the memory-robbing disease. The pivotal Phase II/III clinical trial will involve more than 1,500 patients with early Alzheimer's, the first one of which has now been enrolled. The study is expected to complete in May 2019, according to the clinicaltrials.gov website.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063